Genomics for Drug Discovery, Validation and Clinical Development with AstraZeneca, Pf

[jhodges]

In just two weeks, Cambridge Healthtech Institute's NGS for Drugs, Patients and Clinical Trials will feature a series of opening discussions focused on the utilization of genomic data for decision making during drug development, including steps for discerning and validating targets, model selection, biomarker development, patient stratification and CAP/CLIA-certified operations.

Join leaders from Pfizer, AstraZeneca, Sanofi, Gilead, Genedata and Washington University, as they share their first-hand experiences using genomic information for data driven decision making.

Featured Session Presentations:

Profiling and NGS in Cancer: Challenges and Applications to Targets, Models, and Resistance
Paul Rejto, Ph.D., Director, Computational Biology, Oncology Research Unit, Pfizer, Inc.

Impact of Next-Generation Sequencing on Oncology Drug Discovery and Early Clinical Development
Oleg Iartchouk, Ph.D., Lead Scientist and Lab Head, Applied Genomics, Translational and Experimental Medicine, Sanofi

Uncovering Genetic Interactions in Tumor Cell Lines: A Workflow-Based Approach for NGS Analysis
Benjamin J. Adamczyk, Ph.D., Scientific Account Manager, Genedata USA, Inc.

Devising Methods for Intuitively Handling Huge Data Sets to Simplify Biomarker Discovery
Dongliang Ge, Ph.D., Director, Bioinformatics, Gilead Sciences, Inc.

Stratification of Clinical Trial Subjects Using Biomarkers Developed by Next-Generation Sequencing
Brian Dougherty, Ph.D., Lead, Translational Genomics, Oncology, AstraZeneca

From Theory to Practice: Our First Thousand Samples
Seth D. Crosby, M.D., Director, Alliances and Partnerships, Department of Genetics, Washington University School of Medicine

NGS for Drugs, Patients and Clinical Trials
March 21-22, 2013
Hilton San Diego Resort
Learn more at healthtech.com/ngs-drug-development